1. Anonymous Assesment report for Cimzia. Procedure No EMEA/H/C/001037 www.emea.europa.eu/humandocs/PDFs/EPAR/cimzia/H-1037-en6.pd 2009 1 47
2. CDP870, A novel pegylated, humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA);Keystone,2001
3. UCB Clinical Study Summary Study No.: CDP870-014 http://www.clinicalstudyresults.org/documents/company-study_4348_0.pdf 2008
4. Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial;Choy;Rheumatology (Oxford),2002
5. Efficacy and safety of certolizumab pegol monotherapy in patients with rheumatoid arthritis failing previous DMARD therapy;Fleischmann;Annals of the Rheumatic Diseases,2007